ALMKT:EPA
Mauna Kea Technologies SA
€ 0,092
0,00%
(0,00) 1D
13 nov, 17:35:01 GMT+1 · EUR
search
Alle symbolen
| Symbool | Prijs | Wijziging | Wijzigingspercentage |
|---|
insights_autoBelangrijkste inzichten voor ALMKT genereren…
Openen
€ 0,09
Hoog
€ 0,10
Laag
€ 0,09
Beursw.
18,14 mln.
Gem. vol.
541,14K
Volume
75,16K
Koers/winst-verhouding
0,79
52 wk hoog
€ 0,23
52 wk laag
€ 0,07
WPA
€ 0,12
Uitstaande aandelen
195,26 mln.
Aantal medewerkers
56
Openen
€ 0,09
Hoog
€ 0,10
Laag
€ 0,09
Beursw.
18,14 mln.
Gem. vol.
541,14K
Volume
75,16K
Koers/winst-verhouding
0,79
52 wk hoog
€ 0,23
52 wk laag
€ 0,07
WPA
€ 0,12
Uitstaande aandelen
195,26 mln.
Aantal medewerkers
56
Nieuwsartikelen
Van webbronnen en nieuwspartners
TradingView
·
2 uur geleden
EXCLUSIVE: S&P 500’s Sell-Off Tested Buffered ETFs: Expert Explains Why a 10% Buffer May Not Protect You as Expected
Benzinga
·
47 minuten geleden
VOO & Chill: Inflows Stay Strong as Risk-Off Sentiment Pressures the S&P 500
The Motley Fool
·
3 uur geleden
Warren Buffett's Berkshire Compounded at More Than 19% a Year Over Six Decades, Nearly Double the S&P 500's 10% Return. Can Investors Still Apply That Playbook Today?
Traders Union
·
2 uur geleden
Michael Kantro: Institutional investors focus on stock picking as S&P 500 targets have lost relevance
Profiel
Mauna Kea Technologies is a global medical device company focused on endomicroscopy, the field of microscopic imaging during endoscopy procedures. The company researches, develops and markets tools to visualize, detect, and rule out abnormalities including malignant and pre-malignant tumors or lesions in the gastrointestinal and pulmonary tracts.
The company makes Cellvizio, a probe-based Confocal Laser Endomicroscopy system, which provides physicians and researchers with real-time access to histological information during standard endoscopy procedures through high-resolution cellular imaging of internal tissues.
Cellvizio is used in medical applications such as gastrointestinal endoscopy, pulmonology and urology to help physicians diagnose lesions and make accurate treatment decisions in real-time.
Cellvizio went public in July 2011 and trades on the Euronext Paris exchange. Wikipedia
Over Mauna Kea Technologies SA
CEOSacha Loiseau
Medewerkers56
Opgericht2000
Hoofdkantoor-
SectorHealth Care
Industrie-
Websitemaunakeatech.com